Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology.
The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.
Company Details
- Employees
- 2
- Founded
- 2013
- Address
- 6162 Bristol Parkway, Culver City,california 90230,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://indimolecular.com
- HQ
- Culver City, California
Indi Molecular Questions
Indi Molecular's website is http://indimolecular.com
Indi Molecular's LinkedIn profile is https://www.linkedin.com/company/indi-molecular
Indi Molecular has
2 employees.
View email and phone details for 2
employees at Indi Molecular.
Indi Molecular's industry is
Biotechnology Research
Indi Molecular's top competitors are
Avenzoar Pharmaceuticals, Inc.,
Regeneron,
Ladrx Corporation,
Apollo Biologics,
Microbedx,
Max Biopharma, Inc.,
Dalton Bioanalytics,
Kairos Pharma,
Precisemdx,
Atengen, Inc..
Indi Molecular's categories are Biotechnology Research
Indi Molecular's founding year is 2013
